Redcliffe Lifetech

redcliffelabs.com →

-30%

est. 2Y upside i

HealthcareSeries C

Redcliffe Labs is India's Largest Omni-channel Diagnostics platform

Rank

#1575

Sector

Healthcare / Diagnostics

Est. Liquidity

~4Y

Data Quality

Data: Medium

Redcliffe Labs is the most compelling India diagnostics digitization play.

Last updated: March 21, 2026

Bull (25%)+200%

India diagnostics leader. $150M+ rev. IPO at 8-10x ($1.2-1.5B).

Base (45%)+50%

$80M rev. Profitable. IPO at 5-7x ($400-560M). Strong from $271M.

Bear (30%)-35%

Price war; profitability delayed; incumbent response.

Est. time to liquidity~4.0 years

Preference Stack Risk

severe

Funding Intensity

43%

$116M raised on $271M = 42.8% intensity.

Dilution Risk

moderate

More rounds likely before India IPO.

Secondary Liquidity

none

Indian private company.

Questions to Ask at the Interview

Strategic questions based on Redcliffe Lifetech's data — designed to show you've done your homework.

  • 1

    “EBITDA breakeven timeline?”

  • 2

    “Genomics revenue contribution?”

  • 3

    “Dr. Lal PathLabs competitive response?”

Community

Valuation Sentiment

Our model estimates -30% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.